Michael Hemann
#160,535
Most Influential Person Now
American geneticist
Michael Hemann's AcademicInfluence.com Rankings
Michael Hemannbiology Degrees
Biology
#12687
World Rank
#16179
Historical Rank
Genetics
#1642
World Rank
#1750
Historical Rank
Download Badge
Biology
Michael Hemann's Degrees
- Bachelors Biology Stanford University
Similar Degrees You Can Earn
Why Is Michael Hemann Influential?
(Suggest an Edit or Addition)According to Wikipedia, Michael Timotee Hemann is an American cancer geneticist and associate professor in the David H. Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology. The research in Hemann's laboratory focuses on identification and characterization of genes involved in tumor formation, cancer progression, and chemotherapeutic response.
Michael Hemann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A microRNA polycistron as a potential human oncogene (2005) (3743)
- Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation (2007) (1184)
- The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability (2001) (1128)
- Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control (2004) (564)
- Probing tumor phenotypes using stable and regulated synthetic microRNA precursors (2005) (548)
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants (2005) (463)
- DNA Damage-Mediated Induction of a Chemoresistant Niche (2010) (395)
- An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo (2003) (368)
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress (2017) (311)
- The combined status of ATM and p53 link tumor development with therapeutic response. (2009) (298)
- Topoisomerase levels determine chemotherapy response in vitro and in vivo (2008) (281)
- Stage-specific sensitivity to p53 restoration during lung cancer progression (2010) (254)
- Wild-derived inbred mouse strains have short telomeres. (2000) (212)
- Error-prone translesion synthesis mediates acquired chemoresistance (2010) (197)
- Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. (2009) (187)
- Suppression of tumorigenesis by the p53 target PUMA. (2004) (186)
- Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy (2010) (185)
- Telomere dysfunction triggers developmentally regulated germ cell apoptosis. (2001) (167)
- Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy (2014) (155)
- Transcription elongation factors represent in vivo cancer dependencies in glioblastoma (2017) (147)
- In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression (2009) (147)
- Genes and transposons are differentially methylated in plants, but not in mammals. (2003) (143)
- Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. (2017) (142)
- Defining principles of combination drug mechanisms of action (2012) (139)
- SYK is a critical regulator of FLT3 in acute myeloid leukemia. (2014) (134)
- A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. (2015) (119)
- Expression of Telomerase RNA Template, but Not Telomerase Reverse Transcriptase, Is Limiting for Telomere Length Maintenance In Vivo (2004) (110)
- Exploiting synthetic lethal interactions for targeted cancer therapy (2009) (110)
- A conserved element in Myc that negatively regulates its proapoptotic activity (2005) (108)
- Haploinsufficiency of mTR results in defects in telomere elongation (2002) (107)
- Targeting MTHFD2 in acute myeloid leukemia (2015) (103)
- A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses (2016) (102)
- The Two RNA Ligases of the Trypanosoma brucei RNA Editing Complex: Cloning the Essential Band IV Gene and Identifying the Band V Gene (2001) (102)
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution (2016) (100)
- G-strand overhangs on telomeres in telomerase-deficient mouse cells. (1999) (99)
- A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy (2019) (97)
- Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. (2016) (96)
- Addressing genetic tumor heterogeneity through computationally predictive combination therapy. (2013) (94)
- Intratumor heterogeneity alters most effective drugs in designed combinations (2014) (92)
- A role for PVRL4-driven cell–cell interactions in tumorigenesis (2013) (89)
- A mammalian functional-genetic approach to characterizing cancer therapeutics. (2010) (86)
- Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation (2016) (85)
- Tumor promotion by Mdm2 splice variants unable to bind p53. (2003) (84)
- The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning (2020) (83)
- Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. (2015) (81)
- Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. (2013) (77)
- A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex (2014) (77)
- Understanding resistance to combination chemotherapy. (2012) (73)
- The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia (2017) (72)
- Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. (2019) (70)
- A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. (2014) (68)
- Necroptosis-inducing rhenium(V) oxo complexes. (2015) (68)
- Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia (2018) (65)
- Oncogenes and senescence: breaking down in the fast lane. (2007) (64)
- Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2017) (62)
- Chemotherapeutic resistance: surviving stressful situations. (2011) (58)
- Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? (2017) (58)
- A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth (2015) (56)
- Rev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complex (2018) (44)
- Strain-dependent developmental relaxation of imprinting of an endogenous mouse gene, Kvlqt1. (1998) (41)
- Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer (2017) (39)
- Developmental Arrest of T Cells in Rpl22-Deficient Mice Is Dependent upon Multiple p53 Effectors (2011) (38)
- PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes (2017) (37)
- Nek4 status differentially alters sensitivity to distinct microtubule poisons. (2010) (37)
- Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex. (2017) (37)
- Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. (2016) (36)
- Modeling Tumor Clonal Evolution for Drug Combinations Design. (2016) (35)
- Context-specific roles for paracrine IL-6 in lymphomagenesis. (2012) (35)
- Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. (2017) (32)
- A familial "balanced" 3;9 translocation with cryptic 8q insertion leading to deletion and duplication of 9p23 loci in siblings. (1995) (31)
- Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy (2021) (29)
- The Potent Inhibitory Effect of a Naproxen‐Appended Cobalt(III)‐Cyclam Complex on Cancer Stem Cells (2016) (29)
- The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. (2016) (27)
- Predicting cancer drug mechanisms of action using molecular network signatures. (2013) (26)
- Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. (2016) (21)
- Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. (2019) (21)
- A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency (2015) (21)
- Telomere length, telomere-binding proteins, and DNA damage signaling. (2000) (21)
- Suppression of tumorigenesis by the p 53 target PUMA (2004) (19)
- Trypanosoma brucei RNA Editing Complex (2003) (19)
- Trypanosoma brucei RNA Editing Complex: Band II Is Structurally Critical and Maintains Band V Ligase, Which Is Nonessential (2003) (19)
- Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer (2021) (19)
- Integrated network analyses for functional genomic studies in cancer. (2013) (18)
- Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. (2011) (18)
- Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor (2021) (18)
- Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints (2020) (16)
- Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration (2021) (16)
- Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer (2020) (16)
- REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks (2020) (16)
- The Latitudinal Gradient in Recent Speciation and Extinction Rates of Birds and Mammals (2007) (16)
- Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death (2009) (16)
- Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations (2016) (14)
- The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies (2015) (13)
- Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function (2020) (11)
- Polymerase δ promotes chromosomal rearrangements and imprecise double-strand break repair (2020) (10)
- Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML (2018) (10)
- Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy (2019) (9)
- Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains (2022) (9)
- Tumor Promotion by Mdm 2 Splice Variants Unable to Bind p 531 (2003) (8)
- Rewiring the solid tumor epigenome for cancer therapy (2016) (8)
- A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling (2018) (7)
- From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. (2014) (7)
- In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL. (2018) (7)
- A subset of platinum-containing chemotherapeutic agents kill cells by inducing ribosome biogenesis stress rather than by engaging a DNA damage response (2017) (6)
- Corrigendum: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors (2006) (4)
- A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. (2015) (4)
- Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ib00040a Click here for additional data file. Click here for additional data file. (2016) (4)
- A dynamic view of chemotherapy effectiveness (2019) (4)
- Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel (2021) (4)
- A Platinum(IV) Pro-drug Preferentially Targets IDO Providing Enhanced Ovarian Cancer Immuno-Chemotherapy (2016) (4)
- CARPOOL: A library-based platform to rapidly identify next generation chimeric antigen receptors (2021) (3)
- Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. (2019) (3)
- Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma (2016) (3)
- Reconstitution of Mice with Modified Liver Stem Cells. (2015) (3)
- Unraveling tumor suppressor networks with in vivo RNAi. (2013) (3)
- Integrated regulatory models for inference of subtype‐specific susceptibilities in glioblastoma (2020) (3)
- Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2020) (2)
- Chimeric Tumor and Organ Transplantation Models. (2015) (2)
- Abstract 2957: Uncovering tumor-specific components of the p53 pathway using mouse models and RNAi (2012) (2)
- Reconstitution of Mice with Modified Hematopoietic Stem Cells. (2015) (2)
- CPD Damage Recognition by Transcribing RNA Polymerase II (2007) (2)
- P53 Links Tumor Development to Cancer Therapy (2007) (1)
- Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2018) (1)
- The Development and Use of Genetically Tractable Preclinical Mouse Models (2012) (1)
- Pancreatic Stellate Cells Secrete Deoxycytidine Conferring Resistance to Gemcitabine in PDAC (2019) (1)
- Abstract 5186: Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer (2019) (1)
- NEK4 STATUS INFLUENCES DIFFERENTIAL SENSITIVITY TO MICROTUBULE POISONS (2010) (1)
- A role for PVRL 4-driven cell-cell interactions in tumorigenesis Citation (2013) (1)
- Enhances Oncogenic Transformation Hmga 2 and let-7 Disrupting the Pairing (2007) (1)
- Multiple p53 Effectors Rpl22-Deficient Mice Is Dependent upon Developmental Arrest of T Cells in (2011) (0)
- Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia (2016) (0)
- Abstract PR07: Collateral sensitivity in chemotherapy resistance (2017) (0)
- Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy (2012) (0)
- Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2020) (0)
- Abstract 2358: Uncovering novel mechanisms of resistance in AML using integrative functional genomics (2018) (0)
- Abstract A234: In vivo RNAi screening to identify major players in pancreatic tumor maintenance and growth. (2013) (0)
- Identification of CKMT1B As a New Target in EVI1-Positive AML (2015) (0)
- Abstract A44: The role of PHF6 in maintaining pre-B cell commitment in B-cell acute lymphoblastic leukemia (2016) (0)
- Abstract ED05-03: The development of tractable mouse models to study therapeutic response (2008) (0)
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress (2017) (0)
- Abstract C56: Platinum containing anti-cancer agents as targeted therapeutics (2015) (0)
- A Breast Cancer Stem Cell-Selective , Mammospheres-Potent Osmium ( VI ) Nitrido Complex Citation (2014) (0)
- Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors (2014) (0)
- Targeting Folate Metabolism In Acute Myelogenous Leukemia (2013) (0)
- Depleting hnRNPA 0 enhances lung tumor response to cisplatin and prolongs survival d RNA-binding proteins are critical components of the DNA damage response in vivo (2015) (0)
- NON-HUMAN MAMMALS MODEL OF CANCER human hematopoietic (2010) (0)
- Phagocytic Function of Macrophages Is Impaired By Chronic Lymphocytic Leukemia and high–grade Lymphoma Progression and Can be Highly Effectively Restored for Chemo-Immunotherapy (2014) (0)
- IN THE SPOTLIGHT From Breaking Bad to Worse: Exploiting Homologous DNA Repair Defi ciency in Cancer (2014) (0)
- Loss-of-Function Screening in Hematopoietic Malignancies. (2015) (0)
- Abstract A31: Combination therapies guided by evolution of tumor heterogeneity. (2015) (0)
- Syngeneic Transplants with Modified Chimeric Hematopoietic Tumors. (2015) (0)
- Spotlights on our sister journals: Angew. Chem. Int. Ed. 38/2016. (2016) (0)
- Abstract IA25: Using old mouse models to identify new cancer drug targets (2011) (0)
- Abstract IA10: Targeting intratumoral genetic heterogeneity through rationally designed combination therapy (2013) (0)
- Inside Back Cover: The Potent Inhibitory Effect of a Naproxen‐Appended Cobalt(III)‐Cyclam Complex on Cancer Stem Cells (ChemBioChem 18/2016) (2016) (0)
- Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2017) (0)
- Use of RNAi to Investigate Eµ-myc Lymphomagenesis and Lymphoma Chemoresistance (2004) (0)
- Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2018) (0)
- Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse (2021) (0)
- Nek4 Status Differentially Alters Sensitivity to Microtubule Poisons (2010) (0)
- Abstract 928: Regulatory heterogeneity in glioblastoma multiforme informs novel drug target discovery (2018) (0)
- Abstract 35: Evolution of resistance to glucocorticoid receptor agonists (2016) (0)
- Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening (2022) (0)
- Abstract 2961: The level of mitochondrial apoptotic priming determines cell fate upon p53 restoration (2014) (0)
- Microenvironmental IL-6 Inhibits the Efficacy of Immunogenic Therapy by Suppressing Anti-Cancer Immunity (2020) (0)
- Abstract IA10: Improving existing cancer therapy by targeting the tumor microenvironment (2014) (0)
- Author Correction: Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains (2023) (0)
- Abstract SY22-02: Mammalian functional genetic signatures identify efficacy landscapes of combination chemotherapy (2012) (0)
- A familial {open_quotes}balanced{close_quotes} 3;9 translocation with cryptic 8q insertion leading to deletion and duplication of 9p23 loci in siblings (1994) (0)
- Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy". (2016) (0)
- Band V Gene Essential Band IV Gene and Identifying the RNA Editing Complex : Cloning the brucei Trypanosoma The Two RNA Ligases of the (2001) (0)
This paper list is powered by the following services:
Other Resources About Michael Hemann
What Schools Are Affiliated With Michael Hemann?
Michael Hemann is affiliated with the following schools:
